Newsroom

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” (Excellent) of Associated Electric & Gas Insurance Services Limited (AEGIS) (Hamilton, Bermuda). The outlook of these Credit Ratings (ratings) is stable.The ratings reflect AEGIS’ balance sheet strength, which AM Best assesses as strongest, as well as its strong operating performance, neutral business profile and appropriate enterprise risk manage...

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Badger Meter, Inc. (BMI) Shareholders To Inquire About Securities Fraud Class Action...

MEXICO CITY--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” (Excellent) of Austral Resseguradora S.A. (Austral Re) and Austral Seguradora S.A. Concurrently, AM Best has affirmed the Long-Term ICR of “bbb-” (Good) of Austral Participações S.A. The outlook of these Credit Ratings (ratings) is stable. All companies are domiciled in Brazil and collectively referred to as Austral.The ratings reflect...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD) informe que son actionnaire principal, Advanced Biological Laboratories (ABL), une société de diagnostic luxembourgeoise, a déposé, via ONDE, le dispositif centralisé de dépôt des informations auprès de l’Autorité des marchés financiers (AMF), une information relative à la cession d'un nouveau bloc d'actions ABL Diagnostics dans le cadre d'une opération de gré à gré avec un tiers privé. Le dépôt relatif à cette cessi...

PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE (Paris: GET) Presenter / Corporate Name : Getlink SE - Société Européenne, RCS Paris 483 385 142 37-39 rue de la Bienfaisance, 75008 Paris Date Number of ordinary shares in issue (1) Number of voting rights Theoretical (2) (3) Exercisable (4) 31 May 2026 550,000,000 642,868,087 635,364,950 * * * * (1) The share capital is divided into 550,000,000 ordinary shares of a nominal value of €0.40. (2) In accordance with Article 223-11 of the AMF Gene...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party. The filing relating to this sale can be viewed...

PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE (Paris: GET) Déclarant / Raison sociale : Getlink SE - Société Européenne, RCS Paris 483 385 142 37-39 rue de la Bienfaisance, 75008 Paris Date Nombre d’actions ordinaires composant le capital social (1) Nombre de droits de vote Théoriques (2) (3) Exerçables (4) 31 mai 2026 550 000 000 642 868 087 635 364 950 * * * * (1) Le capital social est divisé en 550 000 000 actions ordinaires d’une valeur nominale de 0,40 euro chacune. (2) Conformément...

Ottawa, ON--(BUSINESS WIRE)--The union representing workers at Ottawa’s Villa Marconi Long - Term Care Centre held an information picket outside the home Friday morning, demanding answers after the management of the home issued layoff notices to five staff. The impacted staff, members of CUPE 4793 work in the Laundry and Environmental Services department. These workers ensure that clothing, bedding, and other linens are clean for the residents of the home. “We are still having issues with suppl...

PUTEAUX, France--(BUSINESS WIRE)--Regulatory News: emeis (Paris:EMEIS): Déclaration au 31 mai 2026   Nombre de titres composant le capital en circulation 161 440 050     Nombre total de droits de vote bruts* 184 264 973     Nombre total de droits de vote exerçables 183 631 723     * Les droits de vote bruts servent de base de calcul pour les franchissements de seuils : ils intègrent les droits de vote attachés aux actions privées de ce droit (auto-détention, contrat de liquidité etc.) voir note...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, pres...